Hepatitis C Still Focus of Liver Meeting
Laird Harrison
November 06, 2015
SAN FRANCISCO — The latest trials of combination hepatitis C drugs aimed at specific genotypes will get top billing at this year's Liver Meeting.
"We have seen phenomenal change in hepatitis C treatment over the last 2 years, and this has not slowed down one bit," said Gary Davis, MD, from MedLogician Consulting in Simpsonville, South Carolina, who is cochair of the American Association for the Study of Liver Diseases scientific program committee.
For the difficult-to-treat patients with genotype 3 and advanced fibrosis, a couple of the new drug combinations are providing "much improved" results, Dr Davis told Medscape Medical News.
"We have seen phenomenal change in hepatitis C treatment over the last 2 years, and this has not slowed down one bit," said Gary Davis, MD, from MedLogician Consulting in Simpsonville, South Carolina, who is cochair of the American Association for the Study of Liver Diseases scientific program committee.
For the difficult-to-treat patients with genotype 3 and advanced fibrosis, a couple of the new drug combinations are providing "much improved" results, Dr Davis told Medscape Medical News.
No comments:
Post a Comment